Drug Profile
Research programme: granisetron buccal - BioDelivery Sciences International
Alternative Names: BEMA GranisetronLatest Information Update: 24 Mar 2022
Price :
$50
*
At a glance
- Originator BioDelivery Sciences International
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Nausea and vomiting
Most Recent Events
- 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical
- 16 Jul 2016 No recent reports of development identified for preclinical development in Nausea and vomiting(Chemotherapy-induced) in USA (Buccal, Film)
- 14 Jan 2010 Preclinical trials in Nausea and vomiting in USA (Buccal)